• Return to Headlines

Epizyme Inc has the Lowest Debt-to-Capital Ratio in the Biotechnology Industry (EPZM, ACHN, MGNX, ENTA, NLNK)

By James Quinn

Below are the three companies in the Biotechnology industry with the lowest Debt-to-Capital ratios. The debt-to-capital ratio is an important measure of how a company is financing its operations along with some insight into its financial strength, relative to other companies in its industry.

Epizyme Inc ranks lowest with a a Debt-to-Capital ratio of 4.7%. Following is Achillion Pharma with a a Debt-to-Capital ratio of 9.3%. Macrogenics Inc ranks third lowest with a a Debt-to-Capital ratio of 9.9%.

Enanta Pharmaceu follows with a a Debt-to-Capital ratio of 15.2%, and Newlink Genetics rounds out the bottom five with a a Debt-to-Capital ratio of 17.8%.

SmarTrend is monitoring the recent change of momentum in Newlink Genetics. Please refer to our Company Overview for the results of our proprietary technical indicators that have been scanning shares of Newlink Genetics in search of a potential trend change.

Keywords: lowest debt-to-capital ratio epizyme inc achillion pharma macrogenics inc enanta pharmaceu newlink genetics

Ticker(s): EPZM ACHN MGNX ENTA NLNK